Mason & Associates Inc Acquires Shares of 2,340 Astera Labs, Inc. $ALAB

Mason & Associates Inc bought a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 2,340 shares of the company’s stock, valued at approximately $235,000.

Several other hedge funds also recently made changes to their positions in the company. Lido Advisors LLC raised its position in shares of Astera Labs by 0.5% during the 4th quarter. Lido Advisors LLC now owns 12,297 shares of the company’s stock valued at $2,046,000 after acquiring an additional 57 shares in the last quarter. Perigon Wealth Management LLC boosted its holdings in Astera Labs by 6.2% in the fourth quarter. Perigon Wealth Management LLC now owns 1,252 shares of the company’s stock worth $208,000 after purchasing an additional 73 shares during the period. Sound Income Strategies LLC increased its stake in Astera Labs by 9.2% during the fourth quarter. Sound Income Strategies LLC now owns 902 shares of the company’s stock valued at $164,000 after purchasing an additional 76 shares during the last quarter. Venturi Wealth Management LLC increased its stake in Astera Labs by 2.6% during the fourth quarter. Venturi Wealth Management LLC now owns 3,284 shares of the company’s stock valued at $546,000 after purchasing an additional 84 shares during the last quarter. Finally, Goldstein Advisors LLC raised its holdings in shares of Astera Labs by 5.8% during the fourth quarter. Goldstein Advisors LLC now owns 1,611 shares of the company’s stock worth $268,000 after purchasing an additional 88 shares during the period. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Transactions at Astera Labs

In other Astera Labs news, Director Bethany Mayer sold 686 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $395.04, for a total transaction of $270,997.44. Following the completion of the transaction, the director directly owned 5,550 shares of the company’s stock, valued at $2,192,472. The trade was a 11.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stefan A. Dyckerhoff sold 3,505 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $450.00, for a total transaction of $1,577,250.00. Following the completion of the transaction, the director owned 57,466 shares of the company’s stock, valued at approximately $25,859,700. This trade represents a 5.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,040,691 shares of company stock worth $507,675,380 over the last 90 days. Corporate insiders own 10.40% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on ALAB. UBS Group raised their price target on shares of Astera Labs from $205.00 to $400.00 and gave the stock a “neutral” rating in a research report on Monday, June 29th. Rothschild & Co Redburn started coverage on shares of Astera Labs in a research report on Friday, May 1st. They set a “neutral” rating and a $153.00 price objective for the company. Barclays increased their price objective on shares of Astera Labs from $165.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Bank of America raised their target price on shares of Astera Labs from $240.00 to $450.00 and gave the stock a “neutral” rating in a report on Tuesday, June 23rd. Finally, Susquehanna lifted their target price on Astera Labs from $155.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. Twelve investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $265.75.

Astera Labs Stock Performance

ALAB stock opened at $417.45 on Friday. Astera Labs, Inc. has a 1 year low of $88.18 and a 1 year high of $499.48. The stock has a market capitalization of $71.56 billion, a price-to-earnings ratio of 282.06, a PEG ratio of 4.51 and a beta of 3.66. The stock’s fifty day moving average is $331.43 and its two-hundred day moving average is $213.25.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.54 by $0.07. Astera Labs had a net margin of 26.72% and a return on equity of 18.49%. The business had revenue of $308.36 million during the quarter, compared to analyst estimates of $292.19 million. During the same quarter in the prior year, the firm earned $0.33 earnings per share. The company’s quarterly revenue was up 93.5% on a year-over-year basis. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. As a group, analysts predict that Astera Labs, Inc. will post 1.84 EPS for the current fiscal year.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.